Skip to main content

Seattle Genetics to buy Cascadian Therapeutics

Cascadian Therapeutics Inc. (Nasdaq: CASC) will be acquired by Seattle Genetics Inc. (Nasdaq: SGEN) for a premium of approximately $614 million in cash. Shares of Cascadian Therapeutics surged $4.16 to close at $10.06 while Seattle Genetics stock tumbled $2.91 to close at $52.30.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.